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Abstract
Background: The high mortality rate associated with epithelial ovarian carcinoma (EOC) reflects diagnosis commonly at an
advanced stage, but improved early detection is hindered by uncertainty as to the histologic origin and early natural history
of this malignancy.
Methodology/Principal Findings: Here we report combined molecular genetic and morphologic analyses of normal human
ovarian tissues and early stage cancers, from both BRCA mutation carriers and the general population, indicating that EOCs
frequently arise from dysplastic precursor lesions within epithelial inclusion cysts. In pathologically normal ovaries,
molecular evidence of oncogenic stress was observed specifically within epithelial inclusion cysts. To further explore
potential very early events in ovarian tumorigenesis, ovarian tissues from women not known to be at high risk for ovarian
cancer were subjected to laser catapult microdissection and gene expression profiling. These studies revealed a quasi-
neoplastic expression signature in benign ovarian cystic inclusion epithelium compared to surface epithelium, specifically
with respect to genes affecting signal transduction, cell cycle control, and mitotic spindle formation. Consistent with this
gene expression profile, a significantly higher cell proliferation index (increased cell proliferation and decreased apoptosis)
was observed in histopathologically normal ovarian cystic compared to surface epithelium. Furthermore, aneuploidy was
frequently identified in normal ovarian cystic epithelium but not in surface epithelium.
Conclusions/Significance: Together, these data indicate that EOC frequently arises in ovarian cystic inclusions, is preceded
by an identifiable dysplastic precursor lesion, and that increased cell proliferation, decreased apoptosis, and aneuploidy are
likely to represent very early aberrations in ovarian tumorigenesis.
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Introduction
The high mortality to incidence ratio associated with epithelial
ovarian carcinoma (EOC) reflects the fact that most of these
cancers have spread beyond the ovary at the time of diagnosis [1].
The good prognosis for patients with disease confined to the ovary
suggests that early detection could lessen mortality substantially.
However, early detection is hindered by the lack of a proven
screening modality. The use of serum CA-125 measurements and
radiologic technology, alone or in combination, has yet to prove
effective in either the high-risk or general populations [2],
although the detection of diagnostic serum proteomic patterns or
biomarker panels holds promise [3,4]. Among the requirements
for development of novel screening strategies for any cancer type
are an understanding of the tumor’s early natural history,
including characterization of the histologic region of origin and
a recognizable premalignant lesion, neither of which has been
elucidated with respect to EOC.
There exist several theories on the pathogenesis of EOC [5].
While it is widely believed that the epithelial component of the
ovary gives rise to the common epithelial ovarian carcinomas [6],
it is not clear whether these cancers originate in the single-cell
layer of surface epithelium or in architectural aberrations of the
surface epithelium. These include surface epithelial-lined clefts and
cortical inclusion cysts, thought to result from post-ovulatory
wound repair, tissue remodeling associated with pregnancy or
aging, paraovarian adhesions, or simply the dynamic interaction
between surface epithelium and underlying stroma [7–9]. A
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related debate centers on whether these morphologic alterations of
surface epithelium are more prevalent in the ovaries of women
who have developed EOC or are at high genetic risk for EOC, and
there are conflicting data with respect to both issues. This is
perhaps not surprising, since from a statistical power perspective, it
would be very difficult to adequately address either hypothesis.
An alternative histopathology-based theory holds that EOC
may arise in components of the secondary Mu¨llerian system,
located within or adjacent to the ovary [10]. This theory is
supported by the high likelihood that at least some proportion of
EOCs of endometrioid or clear cell histologic types arise from
endometriotic lesions of the ovary [6]. In addition, the ovarian
surface epithelium is actually a modified mesothelium, contiguous
with and morphologically resembling the peritoneal mesothelial
lining. Typical EOCs, however, are readily distinguished from the
very rare primary ovarian mesothelioma, and instead resemble
carcinomas arising in true Mu¨llerian-derived tissues such as the
endocervix, endometrium, and fallopian tube, suggesting the
requirement for a metaplastic process if EOCs do in fact arise from
the ovarian surface mesothelium.
Similarly, in an even more radical departure from traditional
models of ovarian tumorigenesis, an emerging theory suggests that
type II (high grade serous) EOCs are perhaps not ovarian cancers
at all, but rather originate in the fallopian tube [11]. This
hypothesis, first developed by Piek and colleagues [12], was based
on the observation of dysplastic morphologic and preneoplastic
molecular alterations in prophylactically removed fallopian tubes
from women with germline BRCA mutations. Subsequently,
several research groups have reported on the striking prevalence
of histopathologic and/or molecular genetic alterations observed
in fallopian tubes from women with BRCA mutations who have
undergone risk-reducing or ovarian cancer surgery. This body of
clinicopathologic and molecular evidence warrants serious con-
sideration of this model as it may apply to at least some proportion
of type II EOCs.
The existence of an identifiable premalignant lesion for EOC is
also debated, a problem compounded by the uncertainty
regarding its histologic origin, and the fact that most EOCs are
of advanced stage and associated with little or no evidence of
preinvasive or normal epithelium at the time of pathological
diagnosis. Candidate precursor lesions include dysplasia [13],
hyperplasia [14], and more subtle alterations involving cellular or
nuclear ‘‘atypia’’ [15,16]. An argument for the development of
ovarian carcinoma ‘‘de novo’’, in the absence of any intermediate
precursor lesion, has also been presented [17].
The advent of new molecular biological and genetic information
coupled with powerful technologies has begun to allow the study of
this problem at a level beyond that of the purely morphologic, as
in the observation of loss of heterozygosity at the BRCA1 and TP53
loci in an ovarian ‘‘carcinoma in situ’’ lesion from a BRCA1
mutation carrier [18]. Here we combine cellular morphologic and
molecular genetic analyses to address the hypothesis that EOC
may arise in ovarian cystic inclusions.
Results
Analysis of Ovarian Tissues from Genetically High Risk
Individuals
Using a combined genetic and morphologic approach, we first
sought evidence that early ovarian carcinoma histogenesis could
be observed in ovarian tissues from BRCA heterozygotes, who have
a 20–40% lifetime risk of ovarian cancer [19]. Two somatic
molecular genetic alterations are minimally required for cancer
development in this population, loss of the wild-type BRCA allele
and, in a majority of cases, mutational inactivation of the TP53
gene [20], both of which may be used to search for preclinical
genetic evidence of ovarian tumorigenesis.
Immunohistochemical analysis of p53 expression was used to
assess the presence of generalized genetic damage and/or TP53
mutation in 37 pathologically normal prophylactic oophorectomy
specimens from BRCA heterozygotes. Focal nuclear p53 expression
was observed in 10 (27%) specimens, invariably confined to
morphologic alterations of the epithelium such as cortical clefts
and inclusion cysts (Figure 1A). Expression of p53 was not
observed in surface epithelial cells or in nonepithelial components
of the ovary, and expression was usually confined to a single focus
of epithelium in each ovary (Figure 1B). To perform a genetic
analysis of these cells, laser catapult microdissection of p53-
immunopositive and immunonegative cells from each ovary was
accomplished, followed by DNA isolation from the pooled cells
from each aberrant histologic focus. Sequence analysis of TP53
revealed a mutation in three p53-immunopositive specimens
(Figure 1C), two from BRCA1 heterozygotes and one from a
BRCA2 heterozygote. All were missense mutations occurring in
exons 5 or 6 (Supplemental Table S1). No mutations were
detected in p53 immunonegative epithelial cells from the same
ovaries.
Next, genetic evidence for loss of the wild-type BRCA allele was
sought in the 10 p53-immunopositive tissue specimens. Epithelial
cells containing the TP53 mutation in specimens PO3 and PO67
also displayed loss of heterozygosity (LOH) of the wild-type
BRCA1 or BRCA2 alleles, respectively (Figure 1D; Supplemental
Table S1). No evidence of BRCA LOH was observed in the cells
from PO49, which contained a TP53 mutation, or in the seven
additional specimens in which p53 overexpression, but not
mutation, was observed. These data indicate that BRCA LOH
and TP53 mutation may coexist in epithelial inclusions prior to
the appearance of a pathological lesion in ovaries from BRCA
heterozygotes, and that TP53 mutation may precede BRCA LOH
in some cases. The frequent overexpression of p53 in the absence
of TP53 mutation in epithelial inclusion cysts of BRCA
heterozygotes suggests that genetic damage, aberrant growth
signals, and/or other types of oncogenic cellular stress [21] are
common in this histologic region of ovaries from these
individuals.
To determine whether these early genetic and morphologic
alterations in clinically normal ovaries were likely to be relevant to
ovarian tumorigenesis, we identified five cases of early stage
ovarian carcinoma from confirmed BRCA heterozygotes (Supple-
mental Table S2). In all five cases, the carcinoma was found to
arise in a morphologic alteration of the surface epithelium, an
inclusion cyst in four cases and a surface papillation in the one case
(OC15). Furthermore, a histologic continuum of normal epithe-
lium, dysplasia, and carcinoma was evident within the foci of
epithelial aberrations in all five cases. (We defined dysplasia
according to general histopathological principles related to
alterations in size, shape, and organization of the cellular
components of a tissue. Specifically, the four criteria used in this
study were: 1) cellular pleomorphism; 2) nuclear atypia; 3) loss of
cellular architectural organization; and 4) absence of stromal
invasion.) These cases were subjected to immunohistochemical
analysis of p53 expression, with strong nuclear overexpression
observed in three of the five carcinomas (OC6, OC7, and OC16).
In the p53-immunopositive cases, similar nuclear overexpression
was observed in the adjacent dysplastic and normal epithelium for
all three cases (Figure 2A-D; Supplemental Figures S1 and S2).
Laser catapult microdissection and DNA isolation from the
normal epithelium, dysplasia, and carcinoma components of each
Ovarian Tumorigenesis
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case were performed, and genetic analysis of TP53 status revealed
a missense mutation in all three p53-immunopositive cases
(Figure 2E; Supplemental Table S2). Additionally, the two p53-
immunonegative tumors were found to harbor frameshift
mutations in TP53 (Supplemental Table S2). Genetic analyses of
DNA from the normal epithelium and dysplasia adjacent to the
carcinomas revealed the presence of the corresponding tumor-
associated TP53 mutation in normal epithelium in two of five
cases, and in dysplasia but not normal epithelium in two additional
cases (Supplemental Table S2).
The various histologic components of each cancer case were
then subjected to genetic analysis for loss of the wild-type BRCA
allele. As expected, BRCA LOH was observed in the invasive
cancer components from all five cases. Analysis of the dysplasia
and normal epithelium adjacent to the carcinomas revealed BRCA
LOH in normal epithelium and dysplasia in two cases, and in
dysplasia but not normal epithelium in one additional case
(Figure 2F; Supplemental Table S2). Either TP53 mutation or
BRCA LOH was evident in dysplastic cells from all evaluable cases.
From a molecular genetic perspective, these data support the
inference drawn from analysis of the prophylactic oophorectomy
specimens, that loss of the wild-type BRCA allele may precede or
follow TP53 mutation during the early stages of BRCA-associated
ovarian tumorigenesis, but that in either case, these genetic events
are closely linked. Both of these molecular genetic scenarios are
consistent with the cell ‘‘death by checkpoint’’ model of BRCA
function [22].
Relevance of Model to Sporadic Ovarian Tumorigenesis
These findings support a model of BRCA-linked ovarian
carcinoma histogenesis in which clonal progression of normal
epithelium through a dysplastic precursor lesion to invasive
carcinoma occurs within epithelial inclusion cysts. We next
determined whether this model is applicable to the more common
sporadic manifestation of ovarian carcinoma. Expression of p53
was assessed in 20 pathologically normal ovaries removed for
benign indications from unselected patients not known to be at
high risk for ovarian cancer. Nuclear p53 expression was apparent
in five (25%) of these cases; immunopositive epithelial cells were
localized to inclusion cysts in four cases and within a cortical
invagination in one case. Expression of p53 was not observed in
surface epithelial cells (Supplemental Figure S3). Sequence analysis
of TP53 using DNA from microdissected immunopositive cells
failed to reveal a mutation in any case. These findings again
suggested that the epithelial cells within ovarian inclusion cysts are
particularly susceptible to oncogenic cell stress, leading to p53
accumulation, but did not provide clear evidence of neoplastic
progression as observed in normal ovarian tissues from women
with BRCA mutations. Others have noted the expression of p53 in
ovarian inclusion cysts or deep invaginations in the presence of
Figure 1. Assessment of p53/TP53 status and BRCA2 allelotype in epithelial inclusion cysts of normal ovary from a BRCA2 6174delT
heterozygote (specimen PO67 in Supplemental Table S1). (A) p53 immunopositive cells from an epithelial inclusion cyst. (B) p53
immunonegative cells from a different epithelial inclusion cyst from the same ovary. (C) Sequence analysis of TP53 in p53 immunopositive cells from
inclusion cyst shown in panel (A). A missense mutation is evident at codon 185 (AGCRAAC; S185N). (D) Loss of the wild-type (wt) BRCA2 allele in DNA
derived from the inclusion cyst (IC) shown in panel (A), with retention of mutant (mut) and wild-type alleles in DNA derived from surface (S)
epithelium from the same ovary.
doi:10.1371/journal.pone.0010358.g001
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cellular ‘‘atypia’’ [23] or ‘‘hyperplasia/dysplasia’’ in prophylactic
oophorectomy specimens [24].
To search further for evidence of multistep neoplastic
progression in ovarian tissues, we examined a consecutive series
of 145 stage I/II ovarian cancers, also from women not known to
be at high genetic risk for ovarian cancer, and from this series
identified 23 cases in which an ovary had retained any evidence of
an epithelial component in addition to the carcinoma. The
carcinoma was found to arise in an inclusion cyst in 21 (91%) of
these cases, in a cortical invagination in one (4%) case, and from
the surface epithelium in one (4%) case. In all 23 cases, the
noninvasive epithelial component consisted of normal epithelium
and dysplasia directly adjacent to the carcinoma (Supplemental
Figures S4 and S5).
To determine the relationship of carcinoma to the adjacent
dysplastic and normal epithelial cells within these lesions,
assessment of TP53/p53 status was performed as before. The
normal and dysplastic epithelium adjacent to cancers contained
Figure 2. Morphological, immunohistochemical, and genetic analyses of early stage ovarian carcinoma arising in a BRCA1 185delAG
heterozygote (specimen OC16 in Supplementary Table S2). (A) Low-power photomicrograph of histologic progression of normal epithelium
(N) to dysplastic epithelium (D) to invasive carcinoma (T) arising within an inclusion cyst. (B,C,D) High-power photpmicrographs of cellular regions of
normal, dysplastic, and carcinoma, respectively, as shown in panel (A). The immunostain is for p53 in panels (A–D). (E) Sequence analysis of TP53
representative of DNA samples from all three cellular components shown in panels (B–D). A missense mutation is evident at codon 282 (CGGRTGG;
R282W). (F) Loss of the wild-type (wt) BRCA1 allele in DNA derived from normal, dysplastic, and tumor cells shown in panels (B–D), with retention of
mutant (mut) and wild-type alleles in surface epithelium from the same ovary.
doi:10.1371/journal.pone.0010358.g002
Ovarian Tumorigenesis
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p53 immunopositive cells in 12 cases (52%) (Supplemental Table
S3; Supplemental Figures S4 and S5); other epithelial cells and
other cell types in the same ovaries were invariably immunone-
gative for p53. These data again indicate the presence of
oncogenic cell stress and p53 upregulation and/or mutation in
normal epithelial and dysplastic cells adjacent to invasive cancers
within inclusion cysts, but not elsewhere within the same ovarian
tissues.
Sequence analysis of TP53 was performed using DNA from
microdissected carcinoma cells from each case. Mutations were
identified 11 of 23 (48%) invasive cancers (Supplemental Table
S3). In two of these cases, the same TP53 mutation was present in
the adjacent dysplastic and normal epithelial components,
confirming their precursor relationship with the associated
invasive carcinoma. In the other nine cases, however, no evidence
of the TP53 mutation was observed in either normal epithelial or
dysplastic cells, implying that in most cases of sporadic ovarian
carcinoma in which TP53 mutation occurs, the mutation is not
detectable until the transition of dysplasia to carcinoma.
Gene Expression Profiles of Ovarian Surface and Cystic
Epithelial Cells
To gain insight into the cellular factors that create an
environment compatible with enhanced DNA damage and
oncogenesis within ovarian epithelial inclusion cysts, we performed
gene expression profiling of microdissected epithelial cells from
ovarian cystic inclusions compared to ovarian surface epithelial
cells from the same pathologically normal ovaries. Differential
expression of 1,443 genes was observed between cystic and surface
epithelial cells (Supplemental Table S4), suggesting the presence of
distinct gene expression phenotypes in the two cell populations.
To test whether the cystic epithelial cell expression profile was
more similar to that of ovarian carcinoma than that of the surface
epithelial cells, a three-way comparison was made incorporating
RNA from ovarian cancers. Differential expression of 657 genes in
cystic epithelium and cancer compared to surface epithelium (418
up-regulated and 239 down-regulated; Supplemental Table S5) was
observed, compared to only 276 genes differentially expressed in
surface epithelium and cancer compared to cystic epithelium (88
up-regulated and 188 down-regulated; Supplemental Table S6).
Notably, however, functional annotation of the differentially
expressed genes (Supplemental Table S5) indicated the presence
of a quasi-neoplastic molecular phenotype in the ovarian cystic
epithelium, with up-regulation of oncogenic factors (e.g., EZH2,
EVI1, MYB, ERBB4, CCNE1, MEIS1, KRAS2, MMP7, VEGF,
MAPK1, MAPK9) and cancer-specific antigens (e.g., TACSTD1,
WFDC2, CD44, CD24), and down-regulation of tumor suppressors
(e.g., GADD45B, GAS1, PTEN, BAX). This degree of co-expression
of cancer-related genes was not evident in the surface epithelial cell/
tumor vs. cystic epithelial comparison (Supplemental Table S6).
To estimate the quality of the expression profiling data, we
performed immunohistochemical analyses of expression for two
arbitrarily chosen gene products, one overexpressed in cyst
epithelium and tumor compared to surface epithelium (TOP2A)
and one underexpressed in cyst and tumor compared to surface
epithelium (FOS), using 56 pathologically normal ovaries
(Figure 3). Semi-quantitative analyses of protein expression
revealed highly statistically significant differences between the
two groups in accordance with the microarray-based data. We
then compared the list of genes differentially expressed in cyst
epithelium and tumor compared to surface epithelium to gene lists
generated in 11 previous studies reporting expression profiles of
ovarian carcinomas compared to one or another normal control
(data not shown). Seventy-one of the genes listed on Supplemental
Table S4 had been previously noted to be differentially expressed
in at least one of these reports, and two genes TACSTD1 (encoding
tumor-associated calcium signal transducer 1) and WFDC2
(encoding whey acidic protein type, four-disulfide core domain
2, or putative ovarian carcinoma marker HE4) had been noted in
five and six previous reports, respectively, suggesting that
overexpression of these genes may play critical roles in the early
stages of ovarian tumorigenesis.
To extract potentially meaningful biological insights form these
hypothesis-generating gene expression profiling studies, we
employed the EASE (Expression Analysis Systematic Explorer)
theme discovery tool [25] to search for evidence of specific
molecular biological pathways that may be disrupted in cystic
ovarian epithelium. Using this approach, three categories of genes
were identified (Supplemental Table S7), including down-regula-
tion of those with signal transduction activity, up-regulation of
those involved in mitotic cell cycle control, and up-regulation of
those involved in microtubule organization and biogenesis.
Notably, forced overexpression of several of the genes from the
third category, including MAP7 [26,27], PCNT2 [28,29], TBCD
[30], PRC1 [31] leads to defective mitotic spindle assembly. From
this analysis, we hypothesized that the extracellular environment
in the ovarian epithelial inclusion cyst causes gene expression
changes leading to attenuation of specific signal transduction
pathways, inappropriate cell cycle progression, and defective
mitotic spindle assembly, resulting in aneuploidy. The latter two
components of this hypothesis could be readily tested.
Cell Proliferation Index and Ploidy
To quantitate the cell proliferation index in epithelial inclusion
cysts and surface epithelial cells of the ovary, we examined an
independent set of 36 pathologically normal ovaries. Cell
proliferation was significantly higher in cyst compared to surface
epithelial cells, and apoptosis was significantly higher in surface
compared to cystic epithelial cells (Tables 1 and 2, and
Supplemental Figure S6). The cell proliferation index (ratio of
cell proliferation to apoptosis) was nine-fold higher in epithelial
cells of inclusion cysts compared to surface epithelial cells of the
normal ovary.
With respect to DNA content, ovarian surface epithelial cells
were completely within the range for diploid control cells, whereas
approximately 17% of the cystic epithelial cells displayed a DNA
content that overlapped with the aneuploid control cell line
(Supplemental Figure S7). The finding of a greater than diploid
DNA content in cystic epithelial cells suggested the presence of
aneuploidy. A portion of the same tissue specimens (n= 11) was
then subjected to fluorescence in situ hybridization (FISH) analysis
using centromeric probes for six chromosomes (1, 3, 6, 7, 8, 11). As
shown in Figure 4 and Table 3, aneuploidy was evident in 9.2% of
cystic epithelial nuclei but in only 0.5% of surface epithelial nuclei
examined. Thus, aneuploidy was found to be relatively common in
histopathologically normal epithelial cells from cystic inclusions,
but very rare in surface epithelial cells.
Discussion
The data support a model in which ovarian cancers frequently
arise within epithelial inclusion cysts, but not the surface epithelium
per se, and that carcinoma may be preceded by a dysplastic precursor
lesion. A substantial degree of oncogenic stress exists within these
epithelial inclusions, as evidenced by the frequent accumulation of
p53. Inclusion cysts display a quasi-neoplastic expression signature;
functional annotation reveals that pathways involving signal
transduction, cell cycle progression, and mitotic spindle formation
Ovarian Tumorigenesis
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are significantly affected. These hypotheses were validated in
experiments demonstrating that the cell proliferation index was
markedly increased in cystic compared to surface epithelial cells,
and that aneuploidy was present in normal-appearing cystic
epithelial cells but not surface epithelial cells.
Allelic imbalance, a surrogate for aneuploidy, has been observed
in small colonic adenomas, the earliest identifiable precursor lesion
of colorectal carcinoma [32]. However, the finding of aneuploidy
in histopathologically normal cells from the likely histologic region
of origin of ovarian cancer suggests that this type of chromosomal
instability is among the earliest of genetic events in the natural
history of ovarian tumorigenesis, and to our knowledge, has no
documented precedent in other human cancer types. It is
important to note in this context that the large majority of
ovarian carcinomas are aneuploid [33,34]. The possibility that
aneuploidy may occur as an early, initiating event and thus a
driving force of tumorigenesis has been argued from the
perspective of a mathematical genetic model [35].
These findings have elements in common with a model that
expands on the concept of cell ‘‘death by checkpoint’’ [22], in
Figure 3. Semiquantitative immunohistochemical analyses of gene products differentially expressed in normal ovarian cystic
epithelium and ovarian carcinoma compared to normal ovarian surface epithelium. (A) Normal ovarian surface epithelium displaying
negative immunstaining for TOP2A. (B) Normal ovarian cystic epithelium displaying strong immunopositivity for TOP2A in two cells. (C) Normal
ovarian surface epithelium displaying immunopositivity for FOS in all cells. (D) Normal ovarian cystic epithelium displaying negative immunostaining
for FOS. Indicated under each pair of photomicrographs are the proportions of immunopositive and immunonegative cellular compartments for the
indicated number of ovarian specimens, with the associated P-values.
doi:10.1371/journal.pone.0010358.g003
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which early human precancerous lesions are characterized by
oncogenic stress (of an undefined nature), causing deregulated
DNA replication and genomic instability, which in turn activates a
DNA damage response that ostensibly delays or prevents cancer
[36,37]. In this model, a strong selective pressure then exists for
mutations that compromise this checkpoint, for example in the
ATM-Chk2-p53 pathway, resulting in tumorigenic progression.
Our data prompt the hypothesis that the unique gene expression
signature observed in ovarian epithelial inclusion cysts represents
the ‘‘oncogenic stress’’ of this model, which in the ovarian
inclusion cyst, leads to aberrant growth signals and DNA damage
in the form of aneuploidy, both of which can cause p53
accumulation. The high prevalence of TP53 mutations in
hereditary [20] and sporadic [38] ovarian carcinomas suggests
that this gene is a frequent mutational target of the selective
pressure for aneuploid cells to overcome this checkpoint. Indeed,
recent data support this concept that proliferation of aneuploid
human cells is limited by a p53-dependent mechanism [39].
The absence of detectable TP53 mutation in pathologically
normal inclusion cysts that contain aneuploid cells provides
evidence from human tissue in vivo that is consistent with the
previous observation in vitro that inactivation of p53 does not, in
and of itself, lead to the development of aneuploidy [40]. Although
we have no evidence that genetic mutation of one or more ‘‘cancer
CIN (chromosomal instability)’’ genes [41] has not occurred in
aneuploid cystic epithelial cells, leading to the development of
aneuploidy, our data are not inconsistent with a model of
widespread epigenetic alterations in the expression of CIN genes,
so designated because reconstitution of any of several of the
epigenetic alterations observed in cystic inclusions confers CIN on
a diploid cell in tissue culture, leading to the self-propagation of
aneuploidy in the absence of specific mutations [26–31]. The
concept of epigenetic events playing an important role in the
development of aneuploidy has been proposed by others [42,43].
Based on the model developed here, mutation of TP53 would
represent one requirement for the progression of cystic aneuploid
cells to dysplasia and carcinoma. However, our data indicate that
TP53 mutation, found in most ovarian carcinomas, usually
becomes detectable in the transition of dysplasia to carcinoma in
sporadic tumors, although earlier in BRCA-linked hereditary
tumors. It was not technically feasible to rule out the possibility
that TP53 is mutated in a small fraction of isolated cells in cystic
inclusions, presumably among those that have developed aneu-
ploidy, and that this mutational event occurs much earlier in
tumorigenic progression. The observation of two sporadic stage I
cancers and two BRCA-linked stage I cancers with the same TP53
mutation detectable in normal, dysplastic, and carcinoma cells
supports this hypothesis. It may be that clonal expansion of a cell(s)
with a specific TP53 mutation is often a late event (i.e., dysplasia to
carcinoma), while isolated aneuploid cells in earlier precursor cell
populations sustain distinct TP53 mutations in a majority of those
cells that progress toward cancer. The genes differentially
expressed in ovarian inclusion cysts and cancers compared to
surface epithelium may provide many candidates for mutated or
aberrantly regulated oncogenes and tumor suppressor genes,
markers for the early detection of ovarian cancer, and clues to the
factors that induce oncogenic stress (i.e., a quasi-neoplastic gene
expression profile) within ovarian cystic inclusions. Knowledge of
the molecular basis for the induction of oncogenic stress
characteristic of inclusion cysts could in turn lead to the
development of novel ovarian cancer prevention strategies.
Materials and Methods
Ethics Statement
All human tissues used in this study were obtained and analyzed
in accordance with a protocol approved by the Institutional Review
Board of the Memorial Sloan-Kettering Cancer Center. Written
informed consent was obtained from all participants in this study.
Immunohistochemistry and TUNEL Assay
For assessment of gene expression by immunohistochemistry,
5 mm sections were prepared from archival, formalin-fixed,
paraffin-embedded tissue specimens and processed using standard
techniques. For p53, a mouse monoclonal antibody (clone DO-7,
Dako) was used at a dilution of 1:500. For FOS, purified rabbit
polyclonal antiserum (SC52, Santa Cruz Biotechnology) was used
at a dilution of 1:400. For TOP2A, a mouse monoclonal antibody
(clone SWT3D1, Oncogene Research Products) was used at a
dilution of 1:300. For Ki-67, a mouse monoclonal antibody
(MIB1, Dakocytomation) was used at a dilution of 1:75. Following
the application of appropriate secondary antibodies, a standard
streptavidin-biotin technique, with diaminobenzidine as chromo-
gen, was used for visualization. The TUNEL assay was performed
using the In Situ Cell Death Detection Kit (Roche Applied
Science) according to the manufacturer’s instructions. All slides
were counterstained with hematoxylin, except those for the Ki-67
assay, which were counterstained with methyl green.
Laser Catapult Microdissection
For isolating individual cells or clusters of cells for genetic
analyses, the PALM Microbeam System (P.A.L.M. Microlaser
Table 1. Cell proliferation indices in ovarian cystic vs. surface
epithelial cells.
Tissue/CellType
No.
Samples
No.
Nuclei
No. Positive
Nuclei (%) P
Cell Proliferation
Ovaries 36 39,382 220 (0.55%)
Surface Epithelial 28 19,216 64 (0.33%)
Cystic Epithelial 32a 20,616 156 (0.76%) 0.04
Apoptosis
Ovaries 28 16,710 1,344 (8.0%)
Surface Epithelial 20 5,544 863 (16%)
Cystic Epithelial 24b 11,166 481 (4.3%) ,0.001
The ‘‘No. Samples’’ represents the number of independent ovarian tissues
analyzed for each cell type. The tissues analyzed for apoptosis were a subset of
those analyzed for cell proliferation. P-values apply to the comparison of values
for cystic vs. surface epithelial cells.
aContained 159 inclusion cysts.
bContained 125 inclusion cysts.
doi:10.1371/journal.pone.0010358.t001
Table 2. Cell proliferation index (CPI).
Cell Proliferation Apoptosis CPI
Surface Epithelial 0.33% 16% 0.02
Cystic Epithelial 0.76% 4.3% 0.18
Ratio of Cyst CPI to Surface CPI 9
The CPI represents the ratio of cell proliferation to apoptosis for each cell type.
doi:10.1371/journal.pone.0010358.t002
Ovarian Tumorigenesis
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Figure 4. Fluorescence in situ hybridization analysis of ploidy in normal ovarian cystic and surface epithelia. All examples shown are
from distinct ovarian specimens. (A) Cystic epithelial cell (arrow) from sample #112 (see Table 2) with three copies of chromosomes 3 (red) and 11
(green). (B) Cystic epithelial cell from sample #84 with three copies of chromosomes 6 (blue) and 11 (green). (C) Cystic epithelial cell from sample
#135 with three copies of chromosome 6 (blue). (D) Cystic epithelial cell from sample #59 with three copies of chromosome 8 (blue). (E) Surface
epithelial cells from sample # 13 with two copies of chromosomes 3 (red), 6 (blue), and 11 (green). (F) Surface epithelial cell from sample #102 with
two copies of chromosomes 3 (red) and 8 (blue).
doi:10.1371/journal.pone.0010358.g004
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Technologies AG) was used. This instrument employs a pulsed,
low-energy 337 nm nitrogen laser coupled to an Axiovert 200
inverted microscope (Carl Zeiss). Groups of cells to be collected
were localized and marked under the microscope and then isolated
by laser microbeam microdissection, which forms a clear gap
around the selected area. Laser-mediated catapulting of the
selected cells resulted in their transfer into the cap of a 0.5 ml PCR
reaction tube (PALM), autoclaved and DEPC-treated before use.
The caps were then placed on tubes containing a digestion mixture
consisting of 10 mg of PCR-grade proteinase K (Roche) in 50 ml of
digestion buffer containing 10 mM Tris-HCl, pH 8.0, 1 mM
EDTA, pH 8.0, and 1% Tween 20. The cells were suspended in
the digestion mixture by microcentrifugation at 14,000 rpm for
2 min. Digestion was accomplished at 37uC for 16 hr, followed by
60uC for 2 hr. The proteinase K was then inactivated by heating
to 95uC for 10 min, and samples were cooled to 4uC for storage.
Prior to PCR-based genetic analyses, DNA was isolated and
concentrated to a volume of 6 ml using the DNA Clean and
Concentrator Kit (Zymo Research).
For isolation of cells from formalin-fixed, paraffin-embedded
tissues, blocks were cooled on ice for 20 min, and 8 mm sections
were prepared using a Microm Cool-Cut microtome at room
temperature. Tissue sections were placed on 1 mm glass slides
coated with a 1.35 mm polyethylene naphthalene membrane
(PALM). Deparaffinization was accomplished by three rinses in
xylenes, then rehydrated with a graded series of ethanol washes
(100–70%), followed by rinsing in deionized water. Tissue sections
were stained with Dako Methyl Green (Dakocytomation) for 20
sec, rinsed with deionized water, then dehydrated with a graded
series (70–100%) of ethanol washes and dried for 30 min at 37uC.
A hematoxylin and eosin-stained tissue section was prepared for
each tissue specimen for pathologic review and to guide
microdissection. Methodology for the isolation of cells from frozen
tissue specimens and RNA preparation is described below under
‘‘Gene Expression Profiling’’.
DNA Sequence and Allelotype Analyses
Sequence analysis of the TP53 gene was accomplished as
previously described in detail [44]. Exons 2–11 and flanking exon-
intron boundaries were analyzed by direct sequence analysis for all
samples. Genotyping and LOH analyses related to the BRCA
founder mutations 185delAG, 5382insC (for BRCA1) and
6174delT (for BRCA2) were accomplished as previously described
[45]. As all tissue specimens analyzed were from individuals
harboring frameshift mutations, the mutant and wild-type alleles
could readily be distinguished; loss of the wild-type allele was
designated when the radiographic intensity of this allele was
#25% of the mutant allele.
Gene Expression Profiling
Normal ovarian tissues and ovarian carcinoma specimens were
flash frozen at the time of surgery, embedded in O.C.T.
Table 3. Cell ploidy as determined by fluorescence in situ hybridization.
Sample No. Cellular Component Triploid (%) Tetraploid (%) No. Probes
13 Surface (n=47) 0 0 6
Cyst (n= 85) 9 (10.6) 4 (4.7) 5
37 Cyst (n= 44) 14 (31.8) 1 (2.3) 4
59 Surface (n=9) 0 0 3
Cyst (n= 161) 14 (8.7) 2 (1.2) 6
84 Surface (n=45) 0 0 6
Cyst (n= 135) 5 (3.7) 0 6
86 Surface (n=56) 1 (1.8) 0 3
Cyst (n= 36) 1 (2.8) 0 5
102 Surface (n=96) 0 0 4
Cyst (n= 43) 2 (4.7) 0 3
112 Surface (n=11) 0 0 3
Cyst (n= 139) 10 (7.2) 2 (1.4) 6
131 Surface (n=36) 1 (2.8) 0 5
Cyst (n= 46) 6 (13.0) 2 (4.3) 5
135 Surface (n=40) 0 0 5
Cyst (n= 90) 4 (4.4) 0 6
140 Surface (n=29) 0 0 3
Cyst (n= 34) 1 (2.9) 0 3
183 Surface (n=41) 0 0 4
Cyst (n= 67) 4 (6.0) 0 5
Total Ovaries Total Cell Type Total Triploid (%) Total Tetraploid (%) Total % Aneuploid
11 Surface (n=410) 2 (0.5) 0 0.5
Cyst (n= 880) 70 (7.9) 11 (1.3) 9.2
The number of surface epithelial cells and number of cystic epithelial cells available for quantitation for each ovarian specimen are listed, followed by the number
(percentage) of nuclei showing triploidy or tetraploidy for at least one of the indicated number of probes. Statistical analysis of these data is described in the Materials
and Methods section; the difference between total percentage of aneuploid cells in cyst vs. surface epithelial cells is significant at a value of P,0.001.
doi:10.1371/journal.pone.0010358.t003
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Compound (Tissue-Tek), and stored at 280uC. A hematoxylin
and eosin-stained tissue section was prepared from each tissue
specimen and examined microscopically for evidence of epithelial
cystic inclusions and intact surface epithelium. Seven such cases
were judged to have sufficient cystic and surface epithelium for
molecular analyses. Ovarian cancer specimens were subjected to a
similar histopathologic review, and 11 cases of advanced stage,
serous ovarian carcinoma were selected for molecular analyses.
For laser catapult microdissection, 8 mm sections from the
corresponding frozen, O.C.T.-embedded specimens were pre-
pared using a Thermo Cryotome at 220uC, then placed on 1 mm
glass slides coated with a 1.35 mm polyethylene naphthalene
membrane (PALM). Tissue sections were stained with Dako
Methyl Green (Dakocytomation) for 2–3 min, rinsed with
deionized water, dehydrated and fixed with a graded series (70–
100%) of ethanol washes, and dried in a vacuum-dessicator at
room temperature for 20–30 min. Tissue sections were then
immediately subjected to laser catapult microdissection.
From the total pool of normal ovarian tissues, approximately
10,000 cells were captured from cystic inclusions and 10,000 cells
were captured from the surface epithelium; a similar number of
cells was obtained from the ovarian carcinomas. Laser catapult
microdissection was accomplished using the PALM MicroBeam
System (as above). After catapulting the cells of interest, each
group of cells (normal ovarian cyst epithelium, normal ovarian
surface epithelium, and ovarian carcinoma) was divided into three
samples each, for a total of nine cell samples. Digestion of cells was
accomplished as described above, followed by total RNA isolation
using the Absolutely RNA Nanoprep Kit (Stratagene). Reverse
transcription was performed using oligo(dT) primers and the
SuperScript Double-Stranded cDNA Synthesis kit (Invitrogen).
Synthesis and linear amplification of cRNA were accomplished by
transcription in vitro using the MessageAmp RNA kit (Ambion).
Two rounds of linear amplification were performed on all nine
samples. Labeling of cRNA was performed during a third round of
amplification using biotinylated nucleotides (Enzo Diagnostics).
The length of labeled cRNA was assessed using the Agilent
Bioanalyzer 2100 nanoAssay; the average length was 600 nt.
Labeled cRNA samples were then hybridized to the Human
Genome U133A GeneChip (Affymetrix), containing 22,215
oligonucleotide-based probe sets, at 45uC for 16 hr. Automated
washing and staining were performed using the Affymetrix Fluidics
Station 400 according to the manufacturer’s protocols, and probe
intensities were quantified using the argon laser confocal
GeneArray Scanner (Hewlett-Packard).
Raw expression data were normalized to a target intensity of
500 to account for differences in global chip intensity, and
expression values were then transformed using the logarithm base
2. Probe sets with very low average expression were eliminated
because their expression measurements were not reliable. A
threshold of 6 on the log scale was used for this purpose.
Differences in absolute gene expression levels between cyst and
surface, tumor and surface, and tumor and cyst were determined
using a two-sample t-test. Results for cyst compared to surface
(Supplemental Table S4), cyst and tumor compared to surface
(Supplemental Table S5), and surface and tumor compared to cyst
(Supplemental Table S6) are presented. All genes with P-values
less than 0.05 are listed. In the latter two tables, genes were listed
when both P-values were less than 0.05 and the fold-changes were
in the same direction.
DNA Content Quantitation
The same formalin-fixed, paraffin-embedded ovarian tissue
specimens used for quantitation of the proliferation index (see
Results section) were used to determine DNA content. These were
unselected, pathologically normal ovaries (n= 36) removed from
women for benign indications who were not at increased genetic
risk for cancer. To avoid sectioning through nuclei, 10 mm sections
were prepared and placed on glass slides as described above for
immunohistochemical analyses. The human breast cancer cell
lines MCF7 and SK-BR-3 were obtained from the American Type
Culture Collection. These cell lines, known to be hypertriploid,
were pelleted, fixed and embedded, and processed as above to
served as positive cellular controls for aneuploidy. Slides were
deparaffinized and rehydrated as for immunohistochemistry,
stained with propidium iodide at 10 mg/ml in the presence of
RNase A, then stored in PBS until DNA quantitation.
Quantitation of DNA content was accomplished using the
ApoTome Imaging System (Carl Zeiss). Slides were viewed on the
Axioplan 2 imaging microscope at 400X magnification, and
images were captured through the AxioCam MR monochrome
digital camera providing a resolution of 130061300 pixels. The
AxioVision 4.1 image acquisition software was used to obtain
optical sections at 0.85 mm intervals through selected nuclei.
Monochrome images were analyzed using the metaMorph
Imaging System (Universal Imaging Corporation). Nuclei were
outlined manually with region tracing tools and an integrated
intensity over the total area of each nucleus was calculated. Each
pixel was assigned an intensity value from 0 (pure black) to 255
(pure white). Overlapping nuclei were excluded from the analysis.
Ploidy Quantitation by Fluorescence in situ Hybridization
The same ovarian tissue specimens used for determination of
proliferation index and DNA content were used for ploidy
analysis. Sections of 4 mm thickness were placed on glass slides,
deparaffinized, and rehydrated as above, then pretreated with
sodium thiocyanate and digested with proteinase according to the
probe manufacturer’s protocol (Vysis). Tissue sections were then
subjected to denaturation at 73uC for 5 min followed by
dehydration in a graded series of ethanol washes (70–100%). Six
chromosome enumeration probes (Vysis), directed toward the
centromeric alpha satellite regions of chromosomes 1, 3, 6, 7, 8
and 11, were labeled with an appropriate fluorophore and
hybridized to tissue specimens using a codenaturation protocol
provided by the manufacturer. Two to three probes were generally
applied together. Slides were coverslipped and incubated at 73uC
for 5 min followed by 42uC for 16 hr, then washed and
counterstained with DAPI. Fluorescence quantitation was accom-
plished using the same technology described above for DNA
quantitation, except that slides were examined at 1000X using
triple or quadruple fluorescence, and each fluorophore was
exposed individually through the appropriate filter. Image overlays
were reconstructed to determine the relationship between specific
nuclei and probes. Only probe signals within nonoverlapping
nuclei were enumerated and included in the analysis. The number
of probes per chromosome per nuclei was recorded for both
surface and cystic epithelial cells as described in the Results
section. The chi-square test was used to assess statistical
significance for the data presented in Table 3.
Additional Statistical Analyses
The chi-square test was used to determine statistical significance
of FOS and TOP2A expression differences between cyst and
surface epithelium of the ovaries examined (Figure 3). Because of
the paired, non-Gaussian nature of the data, a permutation t-test
(100,000 permutations) was used to assess statistical independence
of the cell proliferation (Ki-67) and apoptosis (TUNEL) variables
between cyst and surface epithelial cell populations (Table 1). For
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quantitative comparisons of FOS, TOP2A, and Ki-67 expression,
and of apoptosis between ovarian surface and cystic epithelium, all
cells analyzed were classified as either positive or negative. The
EASE (Expression Analysis Systematic Explorer) theme discovery
tool [43] was used to identify genes comprising molecular
biological pathways potentially overrepresented in microarray-
generated gene expression data (Supplemental Table S7). This
algorithm identifies Gene Ontology (GO) terms that describe a
statistically significant number of genes in a list (Supplemental
Table S5, in this case) compared to the population of genes from
which the list was derived (those represented on the Affymetrix
U133A microarray). A variation of the one-tailed Fisher exact
probability test is used to generate an ‘‘EASE score’’ (P-value) for a
given GO category over-represented on the gene list [43]. For
DNA content quantitation, which involved the comparison of
three groups, mean intensity values of nuclei were compared
between groups using a one-way analysis of variance (ANOVA).
The exact Mann-Whitney statistic was used to determine the
significance of differences in the prevalence of aneuploidy between
cyst and surface epithelium (Table 3); the P-value was based on
100,000 permutations since the data were paired.
Supporting Information
Table S1 Genetic alterations in p53-immunopositive epithelial
cells from ovaries removed prophylactically from BRCA hetero-
zygotes.
Found at: doi:10.1371/journal.pone.0010358.s001 (0.03 MB
DOC)
Table S2 Genetic alterations in stage I ovarian carcinomas from
BRCA heterozygotes.
Found at: doi:10.1371/journal.pone.0010358.s002 (0.03 MB
DOC)
Table S3 Mutation of the TP53 gene in progression of sporadic
ovarian carcinoma.
Found at: doi:10.1371/journal.pone.0010358.s003 (0.03 MB
DOC)
Table S4 Genes differentially expressed in ovarian cystic
epithelium compared to ovarian surface epithelium. ‘‘FC(C)’’
refers to the fold-change in ovarian cystic epithelium compared to
ovarian surface epithelium, followed by the corresponding P-value.
Found at: doi:10.1371/journal.pone.0010358.s004 (0.32 MB
XLS)
Table S5 Genes differentially expressed in ovarian cystic
epithelium and ovarian cancer compared to ovarian surface
epithelium. ‘‘FC(C)’’ refers to the fold-change in ovarian cyst
compared to ovarian surface epithelium, followed by the
corresponding P-value; ‘‘FC(T)’’ refers to the fold-change in
ovarian cancer compared to ovarian surface epithelium, followed
by the corresponding P-value.
Found at: doi:10.1371/journal.pone.0010358.s005 (0.17 MB
XLS)
Table S6 Genes differentially expressed in ovarian surface
epithelium and ovarian cancer compared to ovarian cystic
epithleium. ‘‘FC(S)’’ refers to the fold-change in ovarian surface
epithelium compared to ovarian cystic epithelium, followed by the
corresponding P-value. ‘‘FC(T)’’ refers to the fold-change in
ovarian cancer compared to ovarian cystic epithelium,
Found at: doi:10.1371/journal.pone.0010358.s006 (0.08 MB
XLS)
Table S7 Functional categories of genes differentially expressed
in ovarian cystic epithelial and invasive cancer cells compared to
surface epithelial cells. The gene category name is derived from
Gene Ontology biological process or molecular function catego-
ries, and the P-value represents the ‘‘EASE score’’ as described in
ref. 25.
Found at: doi:10.1371/journal.pone.0010358.s007 (0.03 MB
DOC)
Figure S1 BRCA1-linked ovarian carcinoma case OC7 (see
Supplemental Table S2). The immunostain in all four panels is for
p53. (A) Low-power photomicrograph displaying an inclusion cyst
containing a transition of normal epithelium (N) to dysplasia (D) to
invasive carcinoma (T). (B-D) High-power photomicrographs of
the normal, dysplastic, and invasive cancer components, respec-
tively, shown in panel (A), all strongly immunopositive for p53.
Found at: doi:10.1371/journal.pone.0010358.s008 (10.07 MB
TIF)
Figure S2 BRCA1-linked ovarian carcinoma case OC16 (see
Supplemental Table S2). The immunostain in all four panels is for
p53. (A) Low-power photomicrograph displaying an inclusion cyst
containing a transition of normal epithelium (N) to dysplasia (D) to
invasive carcinoma (T). (B-D) High-power photomicrographs of
the normal, dysplastic, and invasive cancer components, respec-
tively, shown in panel (A), all strongly immunopositive for p53.
Found at: doi:10.1371/journal.pone.0010358.s009 (9.90 MB TIF)
Figure S3 Expression of p53 in unselected, pathologically
normal ovary from patient not known to be at increased genetic
risk for ovarian carcinoma. (A) Epithelium of inclusion cyst
displaying strong p53 immunopositivity. (B) Surface epithelium
from same ovary displaying undetectable levels of p53.
Found at: doi:10.1371/journal.pone.0010358.s010 (5.09 MB TIF)
Figure S4 Sporadic ovarian carcinoma case S48 (see Supple-
mental Table S3). The immunostain in all four panels is for p53.
(A) Low-power photomicrograph displaying an inclusion cyst
containing a transition of normal epithelium (N) to dysplasia (D) to
invasive carcinoma (T). (B-D) High-power photomicrographs of
the normal, dysplastic, and invasive cancer components, respec-
tively, shown in panel A, all strongly immunopositive for p53.
Found at: doi:10.1371/journal.pone.0010358.s011 (0.86 MB TIF)
Figure S5 Sporadic ovarian carcinoma case S65 (see Supple-
mental Table S3). The immunostain in all four panels is for p53.
(A) Low-power photomicrograph displaying an inclusion cyst
containing a transition of normal epithelium (N) to dysplasia (D) to
invasive carcinoma (T). (B-D) High-power photomicrographs of
the normal, dysplastic, and invasive cancer components, respec-
tively, shown in panel (A), all strongly immunopositive for p53.
Found at: doi:10.1371/journal.pone.0010358.s012 (10.06 MB
TIF)
Figure S6 Quantitation of cell proliferation indices in normal
ovarian cystic and surface epithelia. (A,B) Quantitation of cell
proliferation as determined by immunohistochemical assessment
of Ki-67 expression in surface epithelial cells (A), and cystic
epithelial cells (B), from the same ovary. Arrow in panel (B)
indicates cystic epithelial cell immunopositive for Ki-67. (C,D)
Quantitation of apoptosis as determined by TUNEL assay in
surface epithelial cells (C), and cystic epithelial cells (D). Surface
epithelial cells are strongly immunopositive and cystic epithelial
cells are uniformly negative.
Found at: doi:10.1371/journal.pone.0010358.s013 (8.90 MB TIF)
Figure S7 DNA content in cystic and surface epithelial cells
from 36 normal ovaries. Surface epithelial cells (blue bars) are
completely within the range of normal diploid control cells (not
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shown), whereas cystic epithelial cells (red bars) overlap substan-
tially with aneuploid control cells (black bars).
Found at: doi:10.1371/journal.pone.0010358.s014 (2.53 MB TIF)
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